Seek Returns logo

RGC vs. ZTS: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at RGC and ZTS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolRGCZTS
Company NameRegencell Bioscience Holdings LimitedZoetis Inc.
CountryHong KongUnited States
GICS SectorHealth CareHealth Care
GICS IndustryPharmaceuticalsPharmaceuticals
Market Capitalization6.10 billion USD69.47 billion USD
ExchangeNasdaqCMNYSE
Listing DateJuly 16, 2021February 1, 2013
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of RGC and ZTS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

RGC vs. ZTS: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolRGCZTS
5-Day Price Return-7.08%2.42%
13-Week Price Return20.60%-4.38%
26-Week Price Return12,370.00%-4.95%
52-Week Price Return5,568.18%-15.03%
Month-to-Date Return-5.53%7.52%
Year-to-Date Return9,492.31%-3.79%
10-Day Avg. Volume0.26M2.89M
3-Month Avg. Volume2.29M3.14M
3-Month Volatility644.75%22.66%
Beta2.370.92

Profitability

Return on Equity (TTM)

RGC

-54.75%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ZTS

53.21%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

ZTS’s Return on Equity of 53.21% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

RGC vs. ZTS: A comparison of their Return on Equity (TTM) against the Pharmaceuticals industry benchmark.

Net Profit Margin (TTM)

RGC

--

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

Net Profit Margin data for RGC is currently unavailable.

ZTS

27.83%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

A Net Profit Margin of 27.83% places ZTS in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

RGC vs. ZTS: A comparison of their Net Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Operating Profit Margin (TTM)

RGC

--

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

Operating Profit Margin data for RGC is currently unavailable.

ZTS

35.35%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

An Operating Profit Margin of 35.35% places ZTS in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

RGC vs. ZTS: A comparison of their Operating Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Profitability at a Glance

SymbolRGCZTS
Return on Equity (TTM)-54.75%53.21%
Return on Assets (TTM)-51.38%18.27%
Net Profit Margin (TTM)--27.83%
Operating Profit Margin (TTM)--35.35%
Gross Profit Margin (TTM)--71.50%

Financial Strength

Current Ratio (MRQ)

RGC

42.68

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

ZTS

1.76

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

ZTS’s Current Ratio of 1.76 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

RGC vs. ZTS: A comparison of their Current Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Debt-to-Equity Ratio (MRQ)

RGC

0.00

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

ZTS

1.32

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

ZTS’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.32. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

RGC vs. ZTS: A comparison of their Debt-to-Equity Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Interest Coverage Ratio (TTM)

RGC

--

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

Interest Coverage Ratio data for RGC is currently unavailable.

ZTS

15.44

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

ZTS’s Interest Coverage Ratio of 15.44 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

RGC vs. ZTS: A comparison of their Interest Coverage Ratio (TTM) against the Pharmaceuticals industry benchmark.

Financial Strength at a Glance

SymbolRGCZTS
Current Ratio (MRQ)42.681.76
Quick Ratio (MRQ)41.891.04
Debt-to-Equity Ratio (MRQ)0.001.32
Interest Coverage Ratio (TTM)--15.44

Growth

Revenue Growth

RGC vs. ZTS: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

RGC vs. ZTS: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

RGC

0.00%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ZTS

1.24%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

ZTS’s Dividend Yield of 1.24% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

RGC vs. ZTS: A comparison of their Dividend Yield (TTM) against the Pharmaceuticals industry benchmark.

Dividend Payout Ratio (TTM)

RGC

0.00%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ZTS

32.08%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

ZTS’s Dividend Payout Ratio of 32.08% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

RGC vs. ZTS: A comparison of their Dividend Payout Ratio (TTM) against the Pharmaceuticals industry benchmark.

Dividend at a Glance

SymbolRGCZTS
Dividend Yield (TTM)0.00%1.24%
Dividend Payout Ratio (TTM)0.00%32.08%

Valuation

Price-to-Earnings Ratio (TTM)

RGC

--

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

P/E Ratio data for RGC is currently unavailable.

ZTS

25.93

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

ZTS’s P/E Ratio of 25.93 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

RGC vs. ZTS: A comparison of their Price-to-Earnings Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Sales Ratio (TTM)

RGC

--

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

P/S Ratio data for RGC is currently unavailable.

ZTS

7.22

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

ZTS’s P/S Ratio of 7.22 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

RGC vs. ZTS: A comparison of their Price-to-Sales Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Book Ratio (MRQ)

RGC

9.57

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

ZTS

13.95

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

At 13.95, ZTS’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

RGC vs. ZTS: A comparison of their Price-to-Book Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Valuation at a Glance

SymbolRGCZTS
Price-to-Earnings Ratio (TTM)--25.93
Price-to-Sales Ratio (TTM)--7.22
Price-to-Book Ratio (MRQ)9.5713.95
Price-to-Free Cash Flow Ratio (TTM)--30.52